Zogenix (ZGNX +6.7%) moves up after announcing its preliminary Q4 sales figures today. The company expects gross product sales of approximately $13.5M on 145,200 units shipped, with unit volume up approximately 9% sequentially from Q312 and 26% from Q411. For FY12, preliminary unaudited net product revenues were around $36M, up 18% over FY11, but slightly below previously issued guidance of $37M. Separately the drug developer adds that it's filed for a $75M mixed shelf registration.